The Empire State Building Celebrates Romance in NYC with Valentine’s Day Experiences Throughout the Month of February
7.2.2023 18:56:00 EET | Business Wire | Press release
Love is in the air at the Empire State Building (ESB) with a Valentine’s Day celebration that includes an unforgettable proposal package, tower lighting, giveaways, and month-long special offers for visitors this February.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005876/en/
Empire State Building Valentine's Day 86th Floor Observatory (Photo: Business Wire)
- Happily Ever Empire – Each couple that books the popular Happily Ever Empire engagement package – that includes priority access and a private tour of the Observatory with celebratory champagne – for Feb. 10-14 will be gifted a four-night, five-day luxury all-inclusive getaway by Sandals Resorts to the resort of their choice (terms and conditions apply) – that includes the brand new Sandals Dunn’s River that opens in Ocho Rios, Jamaica in May – and a $250 gift card towards a wedding dress courtesy of Kleinfeld Bridal. Happily Ever Empire engagement packages are limited to five bookings per day.
- Getaway Giveaway – Visitors to the Observatory Experience from Feb. 10-14 can enter to win a four-night, five-day all-inclusive resort stay courtesy of Sandals Resorts when they post a photo from the special Valentine’s Day photo corner on the 86th Floor Observatory and tag @sandalsresorts on Instagram.
- Spread the Love – All visitors who purchase tickets on the ESB website during the month of February will receive 10 percent off online orders from Magnolia Bakery, 25 percent off Valentine’s Day flowers from FTD Flowers, and 20 percent off online orders from Tony’s Chocolonely from Feb. 6-14. On Feb. 11 from 2-8 pm, Tony’s Chocolonely will show love with free chocolate heart samples on the 86th Floor Observatory.
- Love Lights – On Feb. 14, the Empire State Building’s world-famous tower lights will shine in a pink heartbeat as a Valentine’s Day gift to New York City.
“The reimagined Observatory at the World’s Most Romantic Building draws visitors from around the world for an authentic experience in the heart of New York City,” said Jean-Yves Ghazi, president of the Empire State Building Observatory. “Our remarkable views provide visitors with the perfect backdrop for an over-the-top date or proposal.”
“It’s the season of romance and as a brand founded on all things love, Sandals Resorts is here to remind couples of the importance of celebrating love,” said Luisana Suegart, director of public relations for the worldwide representatives of Sandals Resorts. “Recent studies from our Institute of Romance found that a key ingredient in thriving relationships is making the time for connection, with couples feeling closest to each other while on vacation and, forget the chocolates, most agreeing that a getaway is the most romantic gift. Gifting these special couples an idyllic Caribbean escape is our way of celebrating such an important milestone.”
Hi-res imagery and b-roll of the Empire State Building, the scheduled Valentine’s Day tower lighting and all the upcoming exclusive offerings can be downloaded here .
More information about the Empire State Building Observatory can be found online.
About the Empire State Building
The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience creates an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. Learn more at www.esbnyc.com. Declared "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, the #1 Attraction in the United States in Tripadvisor’s 2022 Travelers’ Choice Best of the Best, and the #1 New York City attraction by Lonely Planet, it welcomes more than 4 million annual visitors from around the world.
Since 2011, the building has been fully powered by renewable wind electricity, and its many floors primarily house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, Twitter, Instagram, Weibo, YouTube, or TikTok.
Source: Empire State Realty Trust, Inc.
Category: Observatory
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005876/en/
Contact information
MEDIA:
Empire State Realty Trust
Brock Talbot
347-804-7863
btalbot@esrtreit.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
